Home / Spotlights

30/03/22

The new frontier

mRNA_Vccines_Tech_Banners_Landing_Page

Republish

We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

Send to a friend

The details you provide on this page will not be used to send unsolicited email, and will not be sold to a 3rd party. See privacy policy.

Messenger ribonucleic acid — known as mRNA — was discovered in the 1960s, but it has reached new heights of popularity among vaccine developers due to its flexibility and adaptability to emerging infectious diseases.

Now, scientists are exploring the potential for mRNA to combat diseases that have long burdened the world’s poorest communities. This Spotlight explores the development of mRNA vaccines for the Big Three deadliest infectious diseases – tuberculosis, malaria, and HIV/AIDS.

Time for vaccines for the ‘Big Three’

Editorials

Time for vaccines for the ‘Big Three’

28/04/22

Q&A: Start talking about mRNA vaccine access now, say experts

Opinion

Q&A: Start talking about mRNA vaccine access now, say experts

28/04/22

mRNA vaccines: facts, figures and the future

Feature

mRNA vaccines: facts, figures and the future

20/04/22

Can mRNA vaccine tech take on tuberculosis?

Feature

Can mRNA vaccine tech take on tuberculosis?

13/04/22

Hunting the ‘perfect protein’ for malaria mRNA vaccine

Feature

Hunting the ‘perfect protein’ for malaria mRNA vaccine

06/04/22

Cautious optimism for trials of mRNA-based HIV vaccine

Feature

Cautious optimism for trials of mRNA-based HIV vaccine

30/03/22